AACR logo

More articles from Poster Presentations - Novel Combination Immunotherapy Approaches and New Agents

Abstract 1803: HLA-DR-targeting tetrameric IFNα2b immunocytokine has potent in vitro and in vivo activity in myelomas, lymphomas and leukemias
Edmund Rossi, Diane Rossi, Thomas Cardillo, Rhona Stein, Anju Nair, Maria Zalath, David Goldenberg, Chien-Hsing Chang

Cancer Research Apr 2011, 71 (8 Supplement) 1803; DOI: 10.1158/1538-7445.AM2011-1803
Abstract 1781: Lorvotuzumab mertansine (IMGN901) in combination with standard-of-care paclitaxel/carboplatin therapy is highly active in a preclinical xenograft model of ovarian cancer
Kathleen R. Whiteman, Holly A. Johnson, Shanqin Xu, Jan Pinkas, Robert J. Lutz

Cancer Research Apr 2011, 71 (8 Supplement) 1781; DOI: 10.1158/1538-7445.AM2011-1781
Abstract 1798: Effective lymphoma and leukemia therapy with epratuzumab (anti-CD22 IgG) conjugated to SN-38 (Emab-SN-38), with enhanced activity in combination with veltuzumab (anti-CD20 IgG)
Robert M. Sharkey, Thomas M. Cardillo, Serengulam V. Govindan, David M. Goldenberg

Cancer Research Apr 2011, 71 (8 Supplement) 1798; DOI: 10.1158/1538-7445.AM2011-1798
Abstract 1806: TLR2 agonist PSK activates NK cells and enhances the anti-tumor effect of HER2-targeted monoclonal antibody therapy
Hailing Lu, Yi Yang, Ekram Gad, Mary L. Disis

Cancer Research Apr 2011, 71 (8 Supplement) 1806; DOI: 10.1158/1538-7445.AM2011-1806
Abstract 1783: Distinctive effects of the Src-inhibitor, saracatinib (AZD0530), on T-cell activation and differentiation: A basic study to combine Src-inhibitor and vaccine based-cancer immunotherapy
Shinji Takai, Jeffrey Schlom, John W. Greiner

Cancer Research Apr 2011, 71 (8 Supplement) 1783; DOI: 10.1158/1538-7445.AM2011-1783
Abstract 1804: Immuno-chemoradiotherapy for oral cancer: Augmentation of OK-432-induced anti-tumor immunity by tegafur and radiation
Masato Okamoto, Tomoyuki Tano, Kan Shin, Sato Mitsunobu

Cancer Research Apr 2011, 71 (8 Supplement) 1804; DOI: 10.1158/1538-7445.AM2011-1804
Abstract 1799: Can trastuzumab enhance the effectiveness of chemotherapy in patients with resected, HER2-positive, Stage II/III or Stage IV gastric cancer
Takashi Oshima, Chikara Kunisaki, Shoichi Fujii, Roppei Yamada, Yasushi Rino, Munetaka Masuda, Toshio Imada

Cancer Research Apr 2011, 71 (8 Supplement) 1799; DOI: 10.1158/1538-7445.AM2011-1799
Abstract 1796: The impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of gastric cancer
Hiroaki Tanaka, Masaichi Ohira, Kazuya Muguruma, Naoshi Kubo, Hisashi Nagahara, Kenjiro Kimura, Ryosuke Amano, Eiji Noda, Nobuya Yamada, Masakazu Yashiro, Kiyoshi Maeda, Naoyoshi Onoda, Tetsuji Sawada, Bunzo Nakata, Tetsuro Ishikawa, Kosei Hirakawa

Cancer Research Apr 2011, 71 (8 Supplement) 1796; DOI: 10.1158/1538-7445.AM2011-1796
Abstract 1792: Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing regulatory T cells in a model of prostate cancer
Li Shen, Michael Ciesielski, Leigh Ellis, Robert Fenstermaker, Roberto Pili

Cancer Research Apr 2011, 71 (8 Supplement) 1792; DOI: 10.1158/1538-7445.AM2011-1792
Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing
Samantha J. Paston, Rebecca Ashfield, Nathaniel Liddy, Giovanna Bossi, Katherine Adams, Emmet McCormack, Anna Lissina, Tara Mahon, Namir Hassan, Jessie Gavarret, Frayne Bianchi, Nick Pumphrey, Kristin Ladell, Emma Gostick, Andrew K. Sewell, Nikolai Lissin, Peter Molloy, Yi Li, Brian Cameron, Malkit Sami, Emma Baston, Jane Harper, Andrew Johnson, Annelise Vuidepot, Penio Todorov, Rebecca Dennis, Michael Kalos, Carl June, David A. Price, Daniel Williams, Bent K. Jakobsen

Cancer Research Apr 2011, 71 (8 Supplement) 1787; DOI: 10.1158/1538-7445.AM2011-1787

Main menu

User menu

Search

More articles from Poster Presentations - Novel Combination Immunotherapy Approaches and New Agents

Pages

Articles

Info for

About Cancer Research